Skip to content

Association of Cannabis With Cognitive Functioning in Adolescents and Young Adults: A Systematic Review and Meta-analysis

J. C. Scott, Samantha T. Slomiak, Jason D. Jones, Adon F. G. Rosen, Tyler M Moore, R. Gur

JAMA Psychiatry June 1, 2018 DOI: 10.1001/jamapsychiatry.2018.0335 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Meta-analysis Cross-sectional Peer reviewed
Sample size 8,727
Population Adolescents and young adults (mean age 26 years or younger) with frequent or heavy cannabis use compared with participants with minimal cannabis exposure
Topics Cannabis
Key findings Frequent or heavy cannabis use was associated with a small reduction in cognitive functioning (d = -0.25) in cross-sectional studies of youth. The association was not significant in studies requiring abstinence longer than 72 hours (d = -0.08), and the authors conclude the deficits may be of questionable clinical importance and may partly reflect residual acute use or withdrawal effects.

Abstract

Importance: Substantial shifts in perception and policy regarding cannabis have recently occurred, with use of cannabis increasing while its perceived harm decreases. One possible risk of increased cannabis use is poorer cognitive functioning, especially in youth.

Objective: To provide the first quantitative synthesis of the literature examining cannabis and cognitive functioning in adolescents and young adults (with a mean age of 26 years and younger). Data Sources PubMed, PsycInfo, Academic Search Premier, Scopus, and bibliographies of relevant reviews were searched for peer-reviewed, English-language studies from the date the databases began through May 2017. Study Selection Consensus criteria were used to determine study inclusion through abstract and manuscript review. Data Extraction and Synthesis This study followed Meta-analysis of Observational Studies in Epidemiology guidelines. Effect size estimates were calculated using multivariate mixed-effects models for cognitive functioning outcomes classified into 10 domains.

Main Outcomes and Measures: Results from neurocognitive tests administered in cross-sectional studies were primary outcomes, and we examined the influence of a priori explanatory variables on variability in effect size.

Results: Sixty-nine studies of 2152 cannabis users (mean [SD] age, 20.6 [2.8] years; 1472 [68.4%] male) and 6575 comparison participants with minimal cannabis exposure were included (mean [SD] age, 20.8 [3.4]; 3669 [55.8%] male). Results indicated a small overall effect size (presented as mean d) for reduced cognitive functioning associated with frequent or heavy cannabis use (d, −0.25; 95% CI, −0.32 to −0.17; P < .001). The magnitude of effect sizes did not vary by sample age or age at cannabis use onset. However, studies requiring an abstinence period longer than 72 hours (15 studies; n = 928) had an overall effect size (d, −0.08; 95% CI, −0.22 to 0.07) that was not significantly different from 0 and smaller than studies with less stringent abstinence criteria (54 studies; n = 7799; d, −0.30; 95% CI, −0.37 to −0.22; P = .01). Conclusions and Relevance Associations between cannabis use and cognitive functioning in cross-sectional studies of adolescents and young adults are small and may be of questionable clinical importance for most individuals. Furthermore, abstinence of longer than 72 hours diminishes cognitive deficits associated with cannabis use. Although other outcomes (eg, psychosis) were not examined in the included studies, results indicate that previous studies of cannabis in youth may have overstated the magnitude and persistence of cognitive deficits associated with use. Reported deficits may reflect residual effects from acute use or withdrawal. Future studies should examine individual differences in susceptibility to cannabis-associated cognitive dysfunction.

Comparable studies

Other systematic reviews and meta-analyses on cannabis, most cited first.

Study Year Design Participants
Effects of cannabis use on outcomes of psychotic disorders: systematic review People with psychotic disorders, as examined in 13 longitudinal studies 2008 Systematic review
The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample Patients with established schizophrenia (meta-analysis: 572) and patients with... 2010 Meta-analysis and cross-sectional observational study n = 700
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review 2020 Systematic review
Neuroimaging in cannabis use: a systematic review of the literature Cannabis users and controls in neuroimaging studies 2009 Systematic review
Human Laboratory Studies on Cannabinoids and Psychosis. Healthy human subjects and individuals with schizophrenia 2016 Systematic review

Citations in the library

Cited by 56

and 51 more in the library

Cites 27

and 22 more in the library

Explore topics